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standard Trizol protocol. Message RNA was extracted by using PolyAT Tract mRNA Isolation System III (Promega, Madison, WI). Equal amounts of mRNA from fresh tumor samples of the 30 patients were pooled and reversely transcribed to cDNA with random primers, ligated with EcoRI/HindIII linkers, and cloned into T7 select 10-3b vectors arms of phage in T7Select @ system (Novagen, Madison, WI) according to the manufacturer instructions. After in vitro packaging, a phage display library was obtained. The library was titered and amplified as previously described (8) .
Enrichment and screening of phage-peptide clones. To enrich phage clones that bind specifically to autoantibodies associated with NSCLC, we performed 5 cycles of positive and negative selections with pooled sera of the 10 patients with NSCLC and the 10 healthy donors, as previously described (8) . The phage library from the fifth cycle of biopannings was 1:10 8 diluted and allowed to grow on LB agar plates with carbenicillin (Sangon, Shanghai, China). Independent clones were randomly selected and identified with PCR amplification. The clones with inserts were further screened using ELISA with the pooled sera. PCR and ELISA were performed using T7Select (without serum sample), negative controls (with empty phages) and test wells of each selected phage were set in the same plate in triplicates. Normalized reactivity of each selected phage-peptide clone to the patients' sera or the controls' sera was calculated as followed: normalized reactivity = (average optical density [OD] value of the test wells -average OD value of the blank controls) / (average OD value of the negative controls -average OD value of the blank controls). PCR amplicons from high immunoreactive phage-peptide clones were subjected for direct DNA sequencing. After excluding the clones containing the same inserts, we examined the seroreactivity of each clone with individual serum samples harvested from another 30 NSCLC patients before receiving any treatment by using the same ELISA method. The clones with higher seroreactivity than others were then used to predict the probability of NSCLC in an independent set of 180 cases (90 patients with NSCLC and 90 age-, sex-matched healthy controls). Study flow for discovery and validation of the phage-peptide clones is shown in Fig.1 . Table 1 . The seroreactivity of each of the 6 phage-peptide clones did not differ between adenocarcinoma and squamous cell carcinoma (P > 0.05 for each).
To evaluate the ability of the detector for the discrimination of NSCLC patients at early stage and healthy controls, sera of 21 NSCLC patients at I and II stages and the 90 healthy controls were used for the validation. With the use of a logistic regression model with LOOCV, the ability of the panel of 6 phage-peptides to discriminate between the patients at early stage and the healthy controls was significant (P < 0.001), with an AUC of 0.888 (95% CI, 0.781-0.996). Moreover, the most high prediction accuracy was obtained by using support vector machine with LOOCV, with an AUC of 0.962 (95% CI, 0.923-1.001), as shown in Table 1 . Thus, the 6-phage-peptide detector had greater than 92% sensitivity and greater than 85% specificity for NSCLC at early stage. (Table S3) , 30 age-, sex-matched NSCLC patients without chemotherapy, and 30 age-, sex-matched healthy controls. The seroreactivity of each of the six clones was significantly lower in the patients with chemotherapy than in those without chemotherapy (P < 0.01 for each), as shown in Table 2 .
Effect of chemotherapy on the immunoreactivity. To evaluate the effect
The seroreactivity of the 6 phage-peptide clones in the patients with COPD. We examined the normalized reactivity of autoantibodies in 12 patients with COPD, the 90 patients with NSCLC and the 90 healthy controls to the 6 phage-peptide clones. The normalized reactivity of autoantibodies to each of the 6 clones did not have statistical differences between the COPD patients and healthy controls, while the differences were significant between the NSCLC patients and the COPD patients (Table 3) .
Expression of OLFM1 protein in lung cancer. Expression pattern of
OLFM1 protein in 52 pathologically normal lung tissues, 77 lung adenocarcinoma, 40 lung squamous cell carcinoma, and 26 small cell lung cancer specimens was examined using immunohistochemistry. Table S4 shows the characteristics of the 143 patients whose specimens were used in immunohistochemistry. OLFM1 staining was predominantly cytoplasmic in all (Fig.3) . Wilcoxon rank sum test demonstrated that OLFM1
protein was significantly up-regluated in lung adenocarcinoma (P < 0.01) and lung squamous cell carcinoma (P < 0.01) than in the pathologically normal lung tissues, respectively. Furthermore, OLFM1 antigen was significantly up-regulated in adenocarcinoma than in squamous cell carcinoma (P < 0.01) ( 95% CI, 0.10-0.54) were significantly associated with cancer-related death, respectively. However, the normalized reactivity of autoantibodies to each of the 6 phage-peptides was not associated with cancer-related death (Table S7) .
Multivariate Cox regression analysis showed that surgical treatment was solely associated with cancer-related death (adjusted HR, 0.23; 95% CI, 0.10-0.54).
Discussion
In this study, we took 3 steps in the discovery phase to select the 
